J R Grandis

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
    J Rubin Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, PA, USA
    J Natl Cancer Inst 90:824-32. 1998
  2. ncbi Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro
    J R Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Invest 102:1385-92. 1998
  3. ncbi Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
    J R Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:4227-32. 2000
  4. ncbi Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines
    J I Song
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Res 61:5919-25. 2001
  5. ncbi PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells
    Q Sun
    Department of Pathology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Oncogene 28:2348-57. 2009
  6. ncbi Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation
    S E Wheeler
    Department of Otolaryngology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Oncogene 29:5135-45. 2010
  7. ncbi Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer
    M N Lango
    Department of Otolaryngology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Curr Opin Oncol 13:168-75. 2001
  8. ncbi STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines
    W Zhou
    Laboratory and Pathology Service, Pittsburgh VAMC, PA, USA
    Br J Cancer 95:164-71. 2006
  9. ncbi Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells
    M B Miranda
    Department of Medicine, University of Pittsburgh and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Leukemia 17:390-400. 2003
  10. ncbi Gene therapy for the treatment of oral squamous cell carcinoma
    S Xi
    Department of Otolaryngology, University of Pittsburgh School of Medicine, PA, USA
    J Dent Res 82:11-6. 2003

Collaborators

Detail Information

Publications12

  1. ncbi Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
    J Rubin Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, PA, USA
    J Natl Cancer Inst 90:824-32. 1998
    ....
  2. ncbi Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro
    J R Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Invest 102:1385-92. 1998
    ..Thus, TGF-alpha/EGFR-mediated autocrine growth of transformed epithelial cells is dependent on activation of Stat3 but not Stat1...
  3. ncbi Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
    J R Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:4227-32. 2000
    ..These findings provide evidence that constitutively activated Stat3 is an early event in head and neck carcinogenesis that contributes to the loss of growth control by an anti-apoptotic mechanism...
  4. ncbi Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines
    J I Song
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Res 61:5919-25. 2001
    ..Abrogation of constitutive Stat3 activation was seen with LGD1069 treatment. These results suggest that an RXR-selective retinoic acid decreases SCCHN proliferation in part by interfering with TGF-alpha/EGFR autocrine signaling...
  5. ncbi PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells
    Q Sun
    Department of Pathology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Oncogene 28:2348-57. 2009
    ..Our results suggest that PUMA induction through p73 represents a new mechanism of EGFR inhibitor-induced apoptosis, and provide potential ways for enhancing and predicting the sensitivity to EGFR-targeted therapies in HNSCC...
  6. ncbi Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation
    S E Wheeler
    Department of Otolaryngology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Oncogene 29:5135-45. 2010
    ..These results suggest that EGFRvIII mediates HNSCC cell migration and invasion by increased STAT3 activation and induction of HIF1-α, which contribute to cetuximab resistance in EGFRvIII-expressing HNSCC tumors...
  7. ncbi Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer
    M N Lango
    Department of Otolaryngology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Curr Opin Oncol 13:168-75. 2001
    ..As erbB family member interactions and downstream signaling pathways are elucidated in head and neck squamous cell carcinoma, specific targeting strategies may become incorporated into standard treatment approaches...
  8. ncbi STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines
    W Zhou
    Laboratory and Pathology Service, Pittsburgh VAMC, PA, USA
    Br J Cancer 95:164-71. 2006
    ..These findings suggest a molecular basis for the STAT3 dependence of EGFR-mediated prostate tumour progression...
  9. ncbi Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells
    M B Miranda
    Department of Medicine, University of Pittsburgh and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Leukemia 17:390-400. 2003
    ....
  10. ncbi Gene therapy for the treatment of oral squamous cell carcinoma
    S Xi
    Department of Otolaryngology, University of Pittsburgh School of Medicine, PA, USA
    J Dent Res 82:11-6. 2003
    ..This review discusses the techniques used in cancer gene therapy for oral squamous cell carcinoma and summarizes the ongoing strategies that are being evaluated in clinical trials...
  11. ncbi The role of topical antibiotic prophylaxis in patients undergoing contaminated head and neck surgery with flap reconstruction
    J P Simons
    Department of Otolaryngology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Laryngoscope 111:329-35. 2001
    ..However, the addition of topical piperacillin/tazobactam does not appear to enhance the prophylactic benefit of parenteral antibiotics alone...
  12. ncbi Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer
    A Argiris
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Ann Oncol 22:2482-8. 2011
    ..We studied the combination of pemetrexed, a multi-targeted antifolate, and cetuximab, an mAb against the epidermal growth factor receptor, with radiotherapy in poor prognosis head and neck cancer...